title: Myricetin and naringenin inhibit human squamous cell carcinoma proliferation and migration in vitro.
abstract: In this study the potential anticancer effect of 2 flavonoids, myiricetin (MYR) and naringenin (NAR) has been evaluated on an oral squamous cell carcinoma (OSCC) cell line, SCC-25, and HaCaT cells. Both the flavonoids inhibited SCC-25 cell growth, although NAR selectively affected cancer cells without impairing HaCaT cell growth. The cell proliferation inhibition by MYR and NAR was not related to apoptosis induction, but on cell cycle impairment, because a G0/G1 and a G2/M blockage was highlighted following 24 h of treatment in SCC-25 and HaCaT cells, respectively. Western blot analysis showed that MYR induced a decrease of Cyclin D1 in SCC-25 and of Cyclin B1 in HaCaT cells, while NAR negatively modulated Cyclin D1 expression in SCC-25 cells. Wound-healing and cell invasion assays demonstrated that both the flavonoids were able to reduce motility on both SCC-25 and HaCaT cells. In conclusion the results of the present study show the anticancer potential of NAR and MYR on OSCC because they exert cytostatic effect by the impairment of cell cycle progression. Moreover both the flavonoids inhibit cell migration, thus highlighting their potential effect as antimetastatic agents. Therefore, MYR and NAR appear as promising candidate as oral cancer chemopreventive agents.
authors.affiliation: a Department of Surgery and Translational Medicine , University of Milan-Bicocca , Monza , Italy.
authors.forename: Daniele
authors.initials: D
authors.lastname: Maggioni
authors.forename: Gabriella
authors.initials: G
authors.lastname: Nicolini
authors.forename: Roberta
authors.initials: R
authors.lastname: Rigolio
authors.forename: Luisa
authors.initials: L
authors.lastname: Biffi
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Pignataro
authors.forename: Renato
authors.initials: R
authors.lastname: Gaini
authors.forename: Werner
authors.initials: W
authors.lastname: Garavello
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002294:Carcinoma, Squamous Cell / Q000473:pathology*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects*; D056744:Cyclin B1 / Q000235:genetics / Q000378:metabolism; D019938:Cyclin D1 / Q000235:genetics / Q000378:metabolism; D044950:Flavanones / Q000494:pharmacology*; D005419:Flavonoids / Q000494:pharmacology*; D006801:Humans; D009062:Mouth Neoplasms / Q000473:pathology; D015398:Signal Transduction; D014945:Wound Healing / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; C534699:CCNB1 protein, human; C530104:CCND1 protein, human; D056744:Cyclin B1; D044950:Flavanones; D005419:Flavonoids; D019938:Cyclin D1; C040015:myricetin; C005273:naringenin